EntryPoint Capital LLC Sells 653 Shares of Medpace Holdings, Inc. $MEDP

EntryPoint Capital LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 43.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 850 shares of the company’s stock after selling 653 shares during the quarter. EntryPoint Capital LLC’s holdings in Medpace were worth $259,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Brooklyn Investment Group boosted its stake in Medpace by 244.8% in the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Whittier Trust Co. raised its position in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company’s stock valued at $33,000 after acquiring an additional 35 shares during the last quarter. Colonial Trust Co SC lifted its stake in shares of Medpace by 150.0% in the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company’s stock valued at $58,000 after purchasing an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Medpace in the 1st quarter worth $60,000. Finally, Assetmark Inc. boosted its position in shares of Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after purchasing an additional 43 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $463.64 on Friday. The company has a market capitalization of $13.02 billion, a price-to-earnings ratio of 34.47, a P/E/G ratio of 2.85 and a beta of 1.42. The firm’s 50 day simple moving average is $378.86 and its 200 day simple moving average is $335.19. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $501.30.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million for the quarter, compared to the consensus estimate of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period last year, the company posted $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MEDP. Cowen lowered Medpace from a “buy” rating to a “sell” rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft upped their price target on Medpace from $270.00 to $430.00 and gave the company a “hold” rating in a research note on Wednesday, July 23rd. UBS Group downgraded shares of Medpace from a “neutral” rating to a “sell” rating and increased their price target for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. TD Cowen reiterated a “sell” rating and issued a $366.00 price target (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Finally, William Blair reiterated a “market perform” rating on shares of Medpace in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $406.60.

Insider Activity

In other Medpace news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $450.14, for a total transaction of $3,376,050.00. Following the sale, the vice president directly owned 57,500 shares in the company, valued at approximately $25,883,050. This trade represents a 11.54% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel owned 10,343 shares in the company, valued at $4,654,350. This trade represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,450 shares of company stock worth $51,791,251. Corporate insiders own 20.30% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.